Today: 1 February 2026
Subscribe
Browse Category

NASDAQ:RXRX News 18 December 2025 - 12 January 2026

Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

New York, Jan 12, 2026, 11:53 EST — Regular session Shares of Recursion Pharmaceuticals climbed Monday following the release of an updated investor presentation via a Form 8-K filing. The Nasdaq-traded stock gained 4.4%, reaching $4.87 late morning, putting the company’s market cap near $2.1 billion. (SEC) The filing comes as executives and investors gather in San Francisco for the…
12 January 2026
·····
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is ending 2025 with something investors in AI-driven biotech rarely get in the same month: fresh clinical momentum, a high-profile Wall Street upgrade, and renewed attention from Cathie Wood’s ARK funds—all playing out during a shortened Christmas Eve trading session. As of December 24, 2025, RXRX stock is trading around $4.37, up modestly on the…
24 December 2025
····
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals, Inc. stock (NASDAQ: RXRX) heads into the week of December 21, 2025 with investors focused on one thing above all: whether newly released clinical data can turn Recursion’s long-running “AI drug discovery” promise into a credible, repeatable pipeline story that ultimately becomes commercial revenue. The near-term backdrop is noisy. RXRX has been highly volatile for years, and even…
21 December 2025
·····
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) heads into the weekend of December 20, 2025 with investors still digesting a fast-moving sequence of catalysts: fresh clinical data for its lead program REC-4881, a notable JPMorgan upgrade, and a burst of unusually heavy trading volume that has kept the stock in the spotlight. Because U.S. markets are closed on Saturday, the most recent…
20 December 2025
·····
Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next

Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is back in the market’s spotlight on December 18, 2025, after a sharp move higher driven by fresh Wall Street optimism and a growing pile of real-world “proof points” for the company’s AI-driven drug discovery thesis. The setup is classic biotech: a clinical readout starts the spark, an analyst upgrade adds oxygen, and the stock…
18 December 2025
·····

Stock Market Today

  • ASX Reporting Season Poised for Volatility Amid High Investor Sensitivity
    February 1, 2026, 1:31 PM EST. Local fund managers warn of a turbulent Australian Securities Exchange (ASX) reporting season as companies prepare to release half-year results. Auscap Asset Management's chief investment officer Tim Carleton highlights that even minor earnings misses could trigger sharp stock selloffs, reflecting increased volatility seen in recent seasons. Investors remain on edge after one of the most volatile earnings periods in recent memory, with fewer active fund managers amplifying price swings at the stock level. Market participants brace for rapid reactions to corporate performance, emphasizing the challenges ahead in navigating this reporting cycle.
Go toTop